MARKETWIRE.NET

Decode Your Next Market Move

Global Industry Analysts, Inc. (GIA) launches comprehensive analysis of industry segments, market trends, growth drivers, market share, size and demand forecasts on the global G-Protein Coupled Receptors (GPCRs) market. Market segmentation includes Product (Cell Lines, Detection Kits, Cell Culture Reagents and Ligands); Assay Type (cAMP Functional Assays, Calcium Functional Assays, ß-Arrestin Functional Assays, Radioligand Binding & GTPyS Functional Assays, Internalization Assays and Other Assay Types)

Find Out More About Regions, Brands, Dominant, Active & Niche Companies Covered in the Report

24 November 3:44 a.m., Silicon Valley, California - According to the new market research report, the global market for G-Protein Coupled Receptors (GPCRs) is projected to grow at a CAGR of 5.7% reach US$3.9 billion by 2025, driven by growing adoption of the receptors in drug discovery applications. Other factors driving growth include increasing research interest in GPCR drug targets, superior understanding of GPCR membrane structures, identification, and crystallization of newer structures, development of more powerful and efficient GPCR screening tools and technologies, and successful extrapolation of known structural information to other GPCRs of therapeutic interest. There is also a growing demand for related assays due to rise in number of biological drugs, biased agonists and allosteric modulators which target these receptors. Cellular analysis also constitutes a major application of the proteins. G-protein coupled receptor (GPCR) is one of the most potent class of drug targets, and presently constitutes an important part of modern medicinal chemistry. Drugs targeting GPCR have superior therapeutic benefits, as they are more active at cell surface receptors. GPCR-based drugs represent around 35% of the total approved drugs available in the market. GPCRs have intense therapeutic potential for being drug targets. GPCRs facilitate signal transduction in a variety of cell types and therefore have a major role to play in human health and physiology. This highlights the significance of research on GPCR signal transduction. Over a third of all the prescribed drugs tend to target GPCRs. Over the past two decades, there has been much research on understanding working of the receptors at the molecular level. There are also many studies ongoing for developing structure based GPCR drug designing, based on discoveries that various ligands are able to bind to same receptor but stimulate association of other effector proteins to varying extents.

The impact of COVID-19 pandemic remains clearly visible on drug development programs across the board and a large number of clinical research organizations (CROs), drug development enterprises, and university level research teams, have put their projects on hold, thus impacting the market for G-protein-coupled receptors (GPCRs). Although pausing clinical research programs is a known trend, especially the early stage programs, the sector has never been a witness of such high-magnitude mass postponement of projects by a large number of enterprises. Despite the disruption, sponsors in the private as well as public sector are emphasizing proactive measures to ensure the research programs are ready to resume immediately when conditions improve. Such efforts from sponsors strongly indicate that drug discovery spending is poised to stabilize in 2021, following a rather sluggish tide in 2020. At present, the key GPCR drug discovery trends relate to the search for general ligands including antagonists or agonists, and also allosteric modulators and inverse agonists. GPCR-based drug discovery witnessed significant improvements since the development of first-generation drugs. The advancement in structure-based drug design and medicinal chemistry facilitates in selective targeting of receptor sub-types, which further enhances drug safety.

With the availability of abundant data associated with gene expression and gene sequence, identification of new GPCRs became easier. Several companies are engaged in designing a wide range of drug candidates to target the attractive and large opportunities across various therapeutic areas in the GPCR market. GPCR modulators are slowly shifting towards high-prevalence disorders and diseases such as obesity, and diabetes as well as unmet medical conditions such as Alzheimer's disease. GPCR targets have enabled the launch of novel therapeutics such as S1P1 (sphingosine 1-phosphate receptor 1) modulator, fingolimod for reducing relapse rates in Multiple sclerosis patients. In addition, several drugs which target the same GCPR site, are under various stages of development.

Research Methodology
This latest edition of the research study is conducted and published by Global Industry Analysts, Inc., in close collaboration with senior executives in the industry driving strategy, business development, marketing, sales, product management, technology and operations. The views, opinions and findings presented are based validated engagements from a total executive pool size of 923. Among this pool, 183 direct interactions with domain experts were carried out via our proprietary market research platform, MarketGlass. Among the 37 unique participations, a total of 17 validated responses were received as part of this report's primary research outreach program. We are unique in the industry to provide our clients with the validated list executive engagements and the complete project data stack.

Key Competitors Covered in the Report -
Thermo Fisher Scientific, Inc.
PerkinElmer, Inc.
QIAGEN NV
BD Biosciences
Promega Corporation
MilliporeSigma
Enzo Life Sciences, Inc.
Eurofins DiscoverX Corporation
Abcam PLC
Cisbio Bioassays
HD Biosciences Co., Ltd.

Segments Covered in the Report -
Product (Cell Lines, Detection Kits, Cell Culture Reagents, Ligands)
Assay Type (cAMP Functional Assays, Calcium Functional Assays, ß-Arrestin Functional Assays, Radioligand Binding & GTPyS Functional Assays, Internalization Assays, Other Assay Types)
Application (Cancer Research, Metabolic Research, Inflammation Research, CNS Research, Respiratory Research, Cardiovascular Research, Other Applications)

Geographies Analyzed in the Report -
World
USA
Canada
Japan
China
Europe
France
Germany
Italy
UK
Rest of Europe
Asia-Pacific
Rest of World.

View Executive Engagement Dashboards, COVID Impact Questionnaires & Get Complimentary Access to Methodology & Full-Text Secondary Sources

For enquiries e-mail us at sales@strategyR.com .

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIn

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (www.strategyr.com) is the world`s only influencer driven AI powered market research company. Serving more than 41,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for 33 years, offering the widest coverage of topics, geographic markets, competitive brands, and companies profiled.

Contact Us:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: sales@StrategyR.com